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Huntington’s disease (HD) is a neurodegenerative disorder caused by an abnormal expansion of a CAG repeat
encoding a polyglutamine tract in the huntingtin (Htt) protein. The mutation leads to neuronal death through
mechanisms which are still unknown. One hypothesis is that mitochondrial defects may play a key role. In sup-
port of this, the activity of mitochondrial complex II (C-II) is preferentially reduced in the striatum of HD patients.
Here, we studied C-II expression in different genetic models of HD expressing N-terminal fragments of mutant Htt
(mHtt). Western blot analysis showed that the expression of the 30 kDa Iron–Sulfur (Ip) subunit of C-II was sig-
nificantly reduced in the striatum of the R6/1 transgenic mice, while the levels of the FAD containing catalytic
70 kDa subunit (Fp) were not significantly changed. Blue native gel analysis showed that the assembly of C-II
in mitochondria was altered early in N171-82Q transgenic mice. Early loco-regional reduction in C-II activity
and Ip protein expression was also demonstrated in a rat model of HD using intrastriatal injection of lentiviral
vectors encoding mHtt. Infection of the rat striatum with a lentiviral vector coding the C-II Ip or Fp subunits
induced a significant overexpression of these proteins that led to significant neuroprotection of striatal neurons
against mHtt neurotoxicity. These results obtained in vivo support the hypothesis that structural and functional
alterations of C-II induced by mHtt may play a critical role in the degeneration of striatal neurons in HD and that
mitochondrial-targeted therapies may be useful in its treatment.
INTRODUCTION
For reasons that are still unclear, the striatum is preferentially
damaged in a number of acute and chronic pathological condi-
tions, leading to devastating cognitive deficits and abnormal
movements (1). The most studied of these illnesses is Hunting-
ton’s disease (HD).
HDis adominantly inheriteddisordergenerally affectingyoung
adults. Symptoms include involuntary abnormal movements
(chorea, dyskinesia, dystonia), frontal cognitive deficits (e.g.
alterations of adaptation) and psychiatric disturbances (2). The
disease is fatal 15 years after the onset of symptoms. There is
no treatment available to slow the progression of this devastating
disorder.
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HD is caused by a mutation in the gene encoding the protein
huntingtin (Htt) that consists in a CAG triplet repeat expansion
translated into an abnormal polyglutamine (polyQ) tract within
the N-terminal region of the protein (3). While mutant Htt
(mHtt) protein is ubiquitously expressed in the brain, degener-
ation primarily affects the striatum (4).
Mechanisms of HD pathogenesis are likely multifactorial.
The polyQ expansion in mHtt produces a gain of function that
is toxic to neurons through several mechanisms. One major
early event in HD is the alteration of transcription (5). Other
early alterations includes intracellular signaling defects,
axonal transport alterations, deregulated autophagy, alteration
of synaptic function, defects in brain derived neurotrophic
factor transcription, secretion and transport (3), perturbation of
calcium homeostasis (6) and mitochondrial defects (7,8).
Compelling evidence supports a role of energy defects (9) and
more specifically mitochondrial dysfunctions in HD pathogen-
esis (1,10). mHtt interacts with mitochondria, and a reduction
in mitochondrial membrane potential is present in various
genetic models of HD, as well as in lymphoblasts isolated
from HD patients (11,12). mHtt interacts with the protein
DRP1 altering transport and fusion of mitochondria (13). The
biogenesis ofmitochondria inHDmayalsobe altered, especially
through mechanisms involving down-regulation of PGC-1a
(14). How these anomalies progressively change the efficiency
of the respiratory chain and oxidative phosphorylation is
unknown.However, anomalies in the enzymes of the respiratory
chain have been also reported in the striatum of HD patients. In
particular, the activity of mitochondrial complex II (C-II) has
been consistently found to be reduced in the striatum of HD
patients (15,16). The loss of C-II activity in the striatum of HD
patients is associated with a reduced expression of two subunits
of C-II, the Iron–sulfur subunit (Ip, 30 kDa) and FAD subunit
(Fp, 70 kDa) (17). We demonstrated a similar loss of C-II subu-
nits and activity in striatal neurons in primary culture, following
transduction with lentiviral vectors encoding the N-terminal
fragment of mHtt carrying the expanded polyQ tract (17,18).
Of interest, the overexpression of C-II Ip or Fp subunits has
been found to be neuroprotective against mHtt toxicity in this
in vitromodel, suggesting a key role of C-II in HD pathogenesis.
However, the potential mechanisms underlying the reduction in
Ip expression in HD remain unknown. The defects in C-II have
been rarely assessed in vivo in HD animal models and results
are not congruent. No obvious reduction in C-II levels was
observed in a knock-in mouse model of HD (19). A comprehen-
sive review onmitochondria in HD suggested no loss of C-II ac-
tivity in transgenic mouse models of HD (10). However,
longitudinal proteomic analysis of R6/2 mice recently indicated
that the expression of the Ip subunit significantly varies during
the course of the disease, with early increases in expression
(20). Thus, the potential role of C-II defects in HD remains
unclear.
Here, we aimed at elucidating whether the expression of
mHtt may lead to a defect in C-II in vivo. To address this ques-
tion, we examined C-II activity and expression of subunits
constituents in two mouse models of HD (N171-82Q and
R6/1) (21,22) and in a rat model of HD using lentiviral
vectors coding the N-terminal 171 amino acids of mHtt with
82 glutamines (lenti-171-82Q). We observed a preferential
loss of C-II expression and activity in these HD models in
vivo. We then examined whether the overexpression of C-II
subunits using lentiviral vectors exerts neuroprotection
against mHtt toxicity in the rat striatum.
RESULTS
Early decrease in the levels of assembled complex II in brain
mitochondria in transgenic mice expressing an N-terminal
fragment of mHtt
The pathogenic role of the changes in C-II expression or activity
is debated and has not been systematically assessed in different
geneticmodels ofHD(see Introduction). For this reason,weana-
lyzed C-II expression in the striatum of three different models
expressing the N-terminal fragment of mHtt.
Wefirst studied the levels ofC-II subunits Ip and Fp in the stri-
atum of the R6/1 transgenic mouse model of HD. To do this,
western blot analysis was carried out on total protein homoge-
nates. Results showed that the Ip expression levels were signifi-
cantly decreased in the striatum of R6/1 mice when compared
with wild-type littermates at 16 weeks of age (mean+SEM:
wild-type, n ¼ 5, 0.516+ 0.041 OD unit; R6/1, n ¼ 6,
0.387+ 0.040 OD unit; unpaired Student’s t-test, P , 0.05;
Fig. 1).Amild reduction in Fp levels inR6/1was not statistically
significant (wild-type, n ¼ 5, 0.596+ 0.078ODunit; R6/1, n ¼
6, 0.503+ 0.082ODunit; unpairedStudent’s t-test,P . 0.089).
Levels of actin was similar in all groups (wild-type, n ¼ 5,
0.68+ 0.016 OD unit; R6/1, n ¼ 6, 0.66+ 0.029 OD unit; un-
paired Student’s t-test, P, 0.05). Normalization of Ip and Fp
protein to actin levels confirmed selective loss of Ip subunit
(Ip/actin ratio: wild-type, n ¼ 5, 0.762+ 0.061; R6/1, n ¼ 6,
Figure 1. Change in C-II subunits in R6/1 mice. The striatum was dissected out
from 16-week-old mice transgenic for human mHtt exon 1 and analyzed by
western blot. Equal amount of proteins was loaded in each lane. Each lane repre-
sents a differentmouse. (A) Typical western blot of samples showing the expres-
sion of Fp, Ip and actin in striatal samples. (B) Histograms corresponding to the
quantification of the expression of the proteins by image analysis. Note that there
is a significant lossofSDHsubunit Ip,whileonlya trend is seen for theFpsubunit.
Results are the mean+SEM. ∗P , 0.02, unpaired Student’s t-test.
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0.584+ 0.044; unpaired Student’s t-test, P, 0.037; Fp/actin
ratio: wild-type, n ¼ 5, 0.881+ 0.055; R6/1, n ¼ 6, 0.768+
0.051; unpaired Student’s t-test, n.s.; P . 0.168).
Wenext examinedwhether theassemblyofC-IIcouldbemodi-
fied when compared with the other respiratory chain complexes.
For this, mitochondria were prepared using the forebrain of
N171-82Q and control mice and analyzed using blue native poly-
acrylamide gel electrophoresis (BN-PAGE). We found that the
amount of assembled C-II was significantly decreased in brain
mitochondria isolated from 1-month-old N171-82Q mice, when
compared with those from N171-18Q mice (Fig. 2A; mean+
SEM:N171-82Q,n ¼ 5, 51.39+7.18%ofN171-18Q levels; un-
paired Student’s t-test, P, 0.001). At this early time point, the
levels of the other complexes were similar in N171-82Q when
compared with controls (Fig. 2). The comparison between
N171-82Q and both N171-18Q littermates revealed that the de-
fective assembly of C-II persisted at later stages of the disease,
at 2 months of age (N171-82Q, n ¼ 5, 50.78+8.85 of
N171-18Q levels; unpaired Student’s t-test, P, 0.001) and at 3
months of age (N171-82Q, n ¼ 5, 59.43+6.8% of N171-18Q
levels; unpaired Student’s t-test, P, 0.001). The differences
between N181-82Q and non-transgenic littermates became also
significant at these time points (2 months: N171-82Q, n ¼ 5,
mean+SEM: 41.6%+4.1% of non-transgenic littermates
levels; unpaired Student’s t-test, P, 0.001, not shown; 3
months: N171-82Q, n ¼ 4, mean+SEM: 29.1+7.6% of non-
transgenic littermates levels; unpaired Student’s t-test, P ¼
0.0001, not shown). C-IV assemblywas also significantly defect-
iveat these later timepointswhenN171-82Qmicewerecompared
with N171-18Q mice (Fig. 2; N171-82Q at 2 months, n ¼ 5,
58.4+6.7% of N171-18Q levels, P, 0.001; N171-82Q at 3
months, n ¼ 5, 54.9+9.9% of N171-18Q levels, unpaired Stu-
dent’s t-test, P ¼ 0.001). At 3 months, C-IV levels were also
found to be reduced when N171-82Q mice were compared with
those determined in non-transgenic mice (N171-82Q, n ¼ 4,
31.8+5.4% of non-transgenic littermates levels, unpaired Stu-
dent’s t-test, P, 0.001, not shown). Transient time point
changes seen in the amount of assembled C-V and C-III were
seen in the comparison between brain mitochondria isolated
from N171-82Q mice and non-transgenic littermates at 1 (C-V)
and 2 months (C-V and C-III) or in the comparison between
brain mitochondria isolated from N171-18Q mice and non-
transgenic littermates (C-V) at 1 month of age (not shown). Al-
though defects in the functions of these two complexes have
Figure 2.Mitochondrial defects in mitochondria isolated from N171-82Q transgenic mice. Mitochondria were isolated from the forebrain of N171-82Q transgenic
mice and controls (N171-18Q mice) and analyzed by blue native gel (BNG) electrophoresis to detect assembled mitochondrial complexes (A and B) and evaluate
respiration (C) and mtDNA copy number (D). In (A) are shown representative BN-PAGE from samples prepared with mice at different ages. Levels of Tom20 as
detected using western blot were used to control for the quantity of mitochondria in each lane. Note that at 1 month, C-II levels are lower in HD transgenic mice
when compared with controls, while other complexes remained essentially unchanged. (B) Quantification of complexes levels is shown. At later time points,
C-IV levels are also reduced. Results are themean+SEM. ∗P , 0.05. (C) Respiration ofmitochondria preparationwas determined using either glutamate/succinate
5:2 mM (complex II) or substrates glutamate/malate 5:1 mM (complex I) at 2 and 3months of age, respectively. Results are themean+SEM. ∗P, 0.05; ∗∗P, 0.02.
(D) Evaluation of themtDNA copy number assessed by the ratio between COX1mRNA and 18SmRNA levels measured by RT-PCR. Results are themean+SEM.
∗P, 0.05.
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been reported to be relevant in the pathogenesis ofHD (23,24), by
comparing the transgenic N171-18Q with age-matched
N171-82Q, these differences were no longer visible.
Oxygen consumption was also measured on freshly isolated
mitochondria of N171-82Q and control mice. Results revealed
that brain mitochondria from N171-82Q mice at 2 months of
age had a significant defect in the state 3 respiration using glutam-
ate/succinate as C-II substrates (non-transgenic, n ¼ 6, 412.8+
27.2 O2/min/mg of protein; N171-82Q, n ¼ 6, 344.3+
12.1 nmol O2/min/mg of protein; unpaired Student’s t-test, P,
0.05; Fig. 2C). No alteration was seen in the presence of glutam-
ate/malate as C-I substrates (not shown). At 3 months of age,
mitochondria fromN171-82Q showed reduced state 3 respiration
using C-I substrates, when compared with N171-18Q mitochon-
dria (Fig. 2C; N171-18Q, n ¼ 6, 240.9+13.5 O2/min/mg of
protein; N171-82Q, n ¼ 6, 188.1+12.0 nmol O2/min/mg
of protein; unpaired Student’s t-test, P, 0.02). Thus, early
functional alterations of C-II occur in 171-82Q mice.
Todeterminewhether anyothernuclear-drivenmitochondrial
functions other than C-II assembly were defective in transgenic
mHtt models of HD, we quantified the mtDNA copy number
using cytochrome c oxidoreductase (COX)1 versus the nuclear
18S gene amplification rate using quantitative real-time quanti-
tative reverse transcriptase-polymerase chain reaction (qRT-
PCR). This assay requires only a little amount of tissue, and it
was therefore possible to perform it on totalDNA isolated select-
ively from striata of N171-82Q andN171-18Qmice, at different
stages (Fig. 1D). A progressive decline in the amount of mtDNA
was found in the striatum of N171-82Q mice when compared
with N171-18Q. This difference was observed in the animals
at pre-symptomatic ages (1 month) and became bigger there-
after. Statistical analysis showed that the reduction was linked
to genotype and aggravated with age (n ¼ 5–11; two-way
ANOVA; gene, F ¼ 52.98, P, 0.005; age, F ¼ 14.71, P ,
0.027) and differences were significant at 2 and 4 months of
age (P, 0.05 and P , 0.004, respectively, using pairwise mul-
tiple comparison procedurewith theHolm–Sidakmethod). This
observation indicated reduced mitochondrial biogenesis in
N171-82Q mice.
Reduced striatal levels of complex II in a rat model
expressing a short N-terminal fragment of mHtt
We studied whether the expression of mHtt could produce
changes in C-II expression or activity in a rat model of HD
(25). In this rat model, intrastriatal injection of lentiviral
vectors coding mHtt are used, leading to a first phase of mild
neuronal dysfunction (2–8 weeks) followed by a phase of
actual degeneration (10–12 weeks) (26–28). The severity of
the lesions produced by lentiviral vectors encoding mHtt can
be assessed using biochemical markers of neuronal integrity
such as DARPP-32 (dopamine- and cAMP-regulated phospho-
protein, 32 kDa), COX and NeuN (neuronal nuclei marker, i.e.
Fox-3). The series of experiments performed in the rat model
is presented in Figure 3.
We assessed the effect of mHtt on C-II activity using in situ
succinate dehydrogenase (SDH) histochemistry and image
Figure 3. Experimental design to study mitochondrial complex II expression
change induced by mHtt in rats. In all experiments, adult rats received a stereo-
taxic injection of lentiviral vectors (4 ml).Animalswere infectedwith a lentiviral
vector encoding the 171 N-terminal amino acids of mHtt with 82 polyQ repeats
(Htt171-82Q), or the corresponding wild-type fragment with 18 polyQ repeats
(Htt171-18Q) with the reporter fluorescent protein green fluorescent protein
(GFP) or vectors coding the C-II Fp or Ip subunit. In the first experiment (A),
rats were injectedwith lentiviral vectors (4 ml) encodingGFP (left and right stri-
atum, 100 ng/ml of p24) plus either Htt-171-82Q (right striatum, 150 ng/ml of
p24) or Htt-171-18Q (left striatum, 150 ng/ml of p24). Semi-quantitative evalu-
ation of C-II activity using histochemistry of SDH activity was performed at 6
weeks to analyze the co-localization of SDH activity with GFP and the 3Dmeas-
urementofSDHactivity in thearea showingSDHdepletion. In the secondexperi-
ment (B), rats were injectedwith lentiviral vectors (4 ml) encodingGFP (left and
right striatum, 100 ng/ml of p24) plus eitherHtt-171-82Q (right striatum, 150 ng/
ml of p24) or Htt-171-18Q (left striatum, 150 ng/ml of p24). Rats were killed at 6
weeks post-surgery. Striatal punches of the fluorescent area were made to pre-
pared tissue homogenate to performwestern blot analysis of Fp, Ip and actin ex-
pression. In the third experiment (C), rats were injected with lentiviral vectors
(4 ml) encoding GFP (left and right striatum, 100 ng/ml of p24) plus either
lenti-Fp (right striatum, 150 ng/ml of p24) or lenti-Ip (left striatum, 150 ng/ml
of p24). Rats were killed at 4 weeks post-surgery. Striatal punches were made
to prepared tissue homogenate to perform western blot analysis of C-II subunits
Fp and Ip and Tom20. In addition, rats were also injected to perform SDH histo-
chemistry. In the fourth experiment (D), rats were co-injected with lentiviral
vectors (4 ml) encoding wt-Htt171-18Q fragment or mHtt171-82Q fragment
(100 ng/ml of p24) plus either Fp (150 ng/ml of p24), Ip (150 ng/ml of p24) or
GFP as a control of viral load. Rats were killed at 12weeks post-surgery and pro-
cessed for the evaluation of striatal degeneration using DARPP-32 immunohis-
tochemistry and COX histochemistry.
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analysis. We found in a first series of experiments that SDH ac-
tivity was clearly reduced in the striatum of rats at 8 weeks after
infectionwith lenti-Htt171-82Q. Tomore precisely characterize
this phenomenon of SDH loss and determine whether it could
occur earlier in our model, we co-infected the striatum with a
mixture of lenti-Htt171-82Q plus lenti-green fluorescent
protein (GFP) or a mixture of lenti-Htt171-18Q plus lenti-GFP
and examined the animals at 6 weeks post-infection. The injec-
tion of lentiviral vectors coding for GFP allowed us to precisely
delineate the area that was infected using fluorescence detection
[i.e. expressing mHtt or wild-type Htt (wt-Htt)] on frozen
sections (Fig. 4). Thus, we could determine whether the area
presenting a reduction in C-II activity as seen using SDH histo-
chemistry could be superimposed on that expressing mHtt and
GFP. Microscopy observation indeed indicated that the area of
SDH loss co-localizedwithin the area ofGFP as seen on adjacent
sectionswhen lenti-Htt171-82Qwas co-injected (Fig. 4). In con-
trast, when lenti-Htt171-18Q was co-injected with lenti-GFP,
there was no loss of SDH activity (Fig. 4). We performed semi-
quantitative analysis of the average SDH activity of the striatum
along its rostro-caudal extension after infection with
lenti-Htt171-82Q in comparison with SDH activity measured
Figure 4. Lentiviral vectors expressing mHtt fragment leads to a loco-regional reduction in SDH activity in vivo. Animals were infected with a mixture of lentiviral
vector encoding the reporter fluorescent protein GFPmixed with vectors coding Htt171-18Q (left panel) or mHtt171-82Q (right panel). (A) Bright field (SDH histo-
chemistry) orfluorescence imageswere taken fromrepresentative coronal brain sections at the levels of the striatumat 6weekspost-infection.Red linesdelineate areas
of SDH activity loss. Overlay show the area of SDH loss (red) superimposed to areawhere the transgenes are expressed (green). Noteminimal loss of SDH activity in
the control group, in contrast to the striatum injectedwith lenti-Htt171-82Q.Note that the zone presenting the loss of SDH activity is within the area expressingmHtt.
(B) Analysis of the total SDH activity in the striatum along the rostrocaudal. (C) Histograms corresponding to the total SDH activitymeasured in the striatum in both
groups. Scale bar, 1 mm. Data are expressed as the mean+SEM. ∗P , 0.002, n ¼ 6 per group, two-way ANOVA and post hoc Bonferroni/Dunn test.
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in the contralateral striatal area infected with lenti-Htt171-18Q.
Analysis showed that the loss produced by Htt171-82Q was
highly significant (two-way ANOVA; Htt171-82Q effect, F ¼
4.82, P, 0.03; Antero-posterior levels, F ¼ 9.12, P , 0.003,
and post hoc Bonferroni/Dunn test, P , 0.0017), although of
minimal amplitude (10%), since the volume of infection was
small compared with the entire striatum (Fig. 4). In order to
better characterize the loss of SDH activity, tridimentional
(3D) reconstruction was performed to measure SDH activity in
the area of depletion in the striatum infected with
lenti-Htt171-82Q and automatically compared with the activity
in the contralateral striatum injected with lenti-Htt171-18Q as a
control. A statistically significant 30% loss of SDH activity
was found (group, n, mean+SEM; lenti-Htt171-18Q, n ¼ 6,
0.180+ 0.007 OD unit; lenti-Htt171-82Q, n ¼ 6, 0.125+
0.006 OD unit; P , 0.01, paired Student’s t-test). Thus, the ex-
pression of mHtt produces a severe loss of C-II activity in vivo
(Fig. 5).
We next took advantage of the ability to detect GFP on fresh
tissue to prepare tissue extracts containing mostly striatal
neurons expressing Htt171-82Q or Htt171-18Q after infections.
Small punches were made in the GFP-positive area on fresh
slices and processed for western blot analysis. We assessed the
level of expression of the C-II subunit, Ip and Fp at 6 weeks post-
infectionusingwesternblot analysis (Fig. 6).Extracts from striata
infected with lenti-Htt171-82Q displayed similar actin levels
when compared with lenti-Htt171-18Q (group, n, mean+
SEM; lenti-171Htt-18Q, n ¼ 6, 2.52+0.27 OD unit;
lenti-Htt171-82Q, n ¼ 6, 2.79+0.37 OD unit; unpaired Stu-
dent’s t-test, P. 0.58), consistent with equal protein loading
and the absence of major neurotoxic effects of mHtt at these
early time points after infection. The levels of the Core2 subunit
of complex III showed no change between groups, indicating
that mitochondria density was not markedly changed in the HD
context (not shown). The expression of the Ip protein, however,
was significantly reduced at 6 weeks post-infection in the
samplesexpressingHtt171-82Q(Ip/actin ratio; lenti-Htt171-18Q,
n ¼ 6, 0.275+0.037; lenti-Htt171-82Q, n ¼ 6, 0.142+0.033;
unpaired Student’s t-test, P, 0.02). The expression of the Fp
subunit showed a trend to decrease that did not reach significance
Figure 5. Estimation of the loss of SDH activity in the area expressingmHtt in the lentiviral rat model. (A) Bright field (SDH histochemistry) or fluorescence images
were taken from representative coronal brain sections at the levels of the striatum at 6 weeks post-infection and stacked for 3D reconstruction. (B andC) 3D recon-
struction of the brain anatomy (gray)with super-imposition of the volumepresenting a loss of C-II activity (red) in the striatum infectedwith lenti-Htt171-82Q (mHtt)
and its symmetrical projection in the striatum with wt-Htt (green). (D) Histograms corresponding to the regional SDH activity measured in the striatum expressing
Htt171-82Q and symmetrically in the contra-lateral striatum. Scale bar, 1 mm.Data are expressed as themean+SEM. ∗P , 0.01, n ¼ 6 per group, paired Student’s
t-test.
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(Fig. 6; Ip/actin ratio: lenti-Htt171-18Q, n ¼ 6, 2.091+0.252;
lenti-Htt171-82Q, n ¼ 6, 1.685+0.304; unpaired Student’s
t-test, P, 0.02).
Overexpressionof IpandFpC-II subunits isneuroprotective
against mHtt in vivo
To test whether the loss of C-II subunits might play a causal role
in mHtt toxicity in vivo, we examined whether the overexpres-
sion of subunits could be neuroprotective.We attempted to over-
express the subunits of C-II in vivo using lentiviral vectors as we
previously did in cell cultures (17,18). The lentiviral constructs
coding for C-II Ip and Fp were similar to those used for in vitro
experiments but were prepared at higher titres for in vivo infec-
tions. Batches of lenti-Fp and lenti-Ip vectors were first re-tested
in primary cultures of striatal neurons to show that they indeed
induced an increased expression of Fp and Ip proteins (not
shown). For the in vivo experiments, the same batches of
vectors coding C-II subunits were mixed with lenti-GFP and
injected into the striatum. Four weeks later, striatal punches
were made in the GFP-positive area and analyzed by western
blotting. Results showed that levels of the Fp subunit were sig-
nificantly increased in the area infected with lenti-Fp
(Fig. 7A). Ip levels in the striatum infected with lenti-Fp were
not modified. After the infection with lenti-Ip, the levels of the
Ip subunit were increased, while the Fp levels remained un-
changed (Fig. 7B). Using the same experimental paradigm, we
tested histoenzymatically on frozen sections from other infected
animals, if the activity of C-II was increased in the striatal area
where the lenti-Fp or lenti-Ip was injected. Results showed
that Fp or Ip overexpression produced no major increase in
SDH activity (group, n, mean+SEM; lenti-Fp: n ¼ 3,
0.798+ 0.051 OD unit; lenti-Ip, n ¼ 3, 0.754+ 0.021 OD
unit; lenti-LacZ (control), n ¼ 4, 0.782+ 0.009 OD unit; one
wayANOVA, n.s.,P . 0.6) (SupplementaryMaterial, Fig. S1).
We next examined the potential neuroprotective effects of
lenti-Fpor lenti-Ip against lenti-Htt171-82Q toxicity. In theseneu-
roprotection experiments, lenti-GFPwas used as a control of viral
load for infection. After 12 weeks, as expected based on previous
works (25–28), infection of the striatum with lenti-Htt171-82Q
produced local degeneration characterized by loss of DARPP-32
immunohistochemical labeling and COX histochemical labeling
(Fig. 8). In the case of the infection with lenti-Htt171-18Q, no
major lesion was observed except for the small mechanical
trauma produced by the needle during the stereotaxic injection
of viral suspensions. The volume of the loss of DARPP-32 and
COX produced by lenti-Htt171-18Q was minimal (mean+
SEM; n ¼ 10; DARPP-32: 0.075+0.013 mm3; COX: 0.054+
0.019 mm3). Infection with lenti-Htt171-82Q mixed with
lenti-GFP produced much larger lesions readily detected under
Figure 6.Loss ofC-II subunits produced bymHtt in the rat lentiviralmodel. Rats
were infectedwith amixtureof lentiviral vector encoding the reporterfluorescent
protein GFP mixed with vectors coding either Htt171-18Q (left panel) or
mHtt171-82Q (right panel). Small striatal samples expressing mHtt or wt-Htt
were dissected out at 6 weeks and analyzed by western blotting. Equal amount
of proteins was loaded in each lane. Each lane represents a different rat. (A) A
typical western blot of samples obtained at 6 weeks post-infection showing ex-
pression of Fp, Ip and actin in striatal samples. (B) Histograms corresponding
to the quantification of the expression of the proteins by image analysis. Note
that there is a significant loss of SDH subunit Ip, while only a trend is seen for
the Fp subunit. Results are the mean+SEM. ∗P , 0.02, n ¼ 6 per group, un-
paired Student’s t-test.
Figure 7. Study of the transduction efficacy of lentiviral vectors coding C-II Ip
and Fp subunits in vivo. Rats received intrastriatal injection of lenti-Fp (A) and
lenti-Ip (B) mixed with lenti-GFP and the infected area was dissected out 4
weeks later using fluorescence detection for western blot analysis. Representa-
tive western blots are shown in upper panel. Control rats have been injected
with lentiviral vectors coding the reporter gene LacZ. Results are the mean+
SEM. ∗P, 0.01, n ¼ 4–6 per group, unpaired Student’s t-test.
Human Molecular Genetics, 2013, Vol. 22, No. 19 3875
microscopeobservation (n ¼ 9;DARPP-32: 1.550+0.115 mm3;
COX: 1.855+0.132 mm3). Co-infection with lenti-Htt171-82Q
mixedwith lenti-Fp produced a partial (30%) but significant re-
duction in the volume of striatal lesions produced by
lenti-Htt171-82Q plus lenti-GFP as seen using DARPP-32
and COX staining (Fig. 8) (n ¼ 10; DARPP-32: 1.159+
0.080 mm3; COX:1.433+0.137 mm3; P, 0.002 and P,
0.02, respectively, when compared with lenti-Htt171-82Q+
lenti-GFP, ANOVA and the post hoc Bonferroni test). Co-infec-
tion with lenti-Ip produced a stronger (50%) reduction in the
mHtt-induced lesion compared with control (Fig. 8) (n ¼ 12;
DARPP-32: 0.917+0.145 mm3; COX: 1.008+0.144 mm3;
P, 0.005 and P, 0.004, respectively, when compared with
lenti-Htt171-82Q+lenti-GFP, ANOVA and the post hocBonfer-
roni test). Thus, the overexpression of Fp and Ip is neuroprotective
against mHtt toxicity.
We also examined whether the overexpression of the Ip
subunit could have an effect on mHtt-containing aggregates.
The number and the size of aggregates detected by EM48 immu-
nohistochemistry in rats infected with lenti-Htt171-82Q were
not significantly different between rats co-infected with
lenti-Ip and animals infected with lenti-GFP. This indicated no
major effect of Ip overexpression on mHtt aggregation (Supple-
mentary Material, Fig. S2).
DISCUSSION
The present study shows that the assembly of C-II in the mito-
chondria is defective in the N171-82Q transgenic mouse
model of HD expressing the N-terminal part of mHtt. This is ac-
companied by a reduction in mitochondrial biogenesis.
Decreased assembly of C-II corresponds to a reduced activity,
as seenbyoxygenconsumption assays.Wealso show that the ex-
pressionon the Ip subunit ofC-II is significantly decreased in two
different genetic models expressing short N-terminal fragments
of mHtt. Moreover, we show that the overexpression of the C-II
subunit Fp protein and, more efficiently, the Ip protein can
prevent mHtt-induced degeneration of striatal neurons in vivo.
TheN171-82Qmousemodels we examined indicated that the
assembly of C-II was defective at relatively early stage of the
disease. Indeed, loss of C-II assembly was observed at 1 month
of age in these HD mice expressing an expanded polyQ tract
when compared with transgenic mice expressing the wild-type
fragmentwith 18glutamines.At this early timepoint, the expres-
sion of the other mitochondrial complexes appears unchanged
when compared with controls. Later, BN-PAGE analysis
showed that the C-II levels were persistently low and that the
C-IV levels in the respiratory chain were also found to be
reduced. The results obtained by BN-PAGE functionally corre-
sponded to the results obtained by the classic respirometry
assays. Reduced assembly ofC-II inN171-82Qmice is followed
by a reduction in the activity of the complex. Indeed, oxidative
phosphorylation/O2 consumption evaluated using succinate as
a substrate was significantly decreased in N171-82Qmice. Con-
sistent with C-II defects, we found that the total levels of the Ip
protein are reduced in the striatum of a different mouse model,
the R6/1 line at 16 weeks of age, an early stage in these mice
that die around 30–35 weeks (29). Western blot analyses
showed that the loss of Ip is relatively selective, since the
levels of the Fp subunit are not significantly reduced in this
mousemodel. A loss of C-II activity alongwith a preferential re-
duction in Ip subunit levels were also found 6 and 8 weeks after
intrastriatal infection in the lentiviral model of HD in rats. This
Figure 8.Neuroprotective efficacy of Fp and Ip againstmHtt neurotoxicity in vivo. Ratswere co-injectedwith lentiviral vectors encodingwt-Htt171-18Q fragment or
mHtt171-82Qplus either, Fp, Ip orGFPas a control of viral load.Ratswere killed at 12weeks post-surgery andprocessed for histological evaluation. (A) Photomicro-
graphs of representative lesions seen in the different groups of rats o characterize striatal degeneration using DARPP-32 immunohistochemistry. Scale bar, 200 mm.
Histograms in (B) represent the volumeof lesionsproduced in thedifferent conditionswhenassessedby theCavalierimethodusingDARPP32 immunohistochemistry
(left) and cytochrome c oxidase (Cyt. Oxidase) histochemistry (right). Note that the volume of striatal lesions produced by mHtt is significantly reduced by overex-
pressing Fp and Ip proteins when compared with control (GFP). Data are the mean+SEM. ∗P , 0.01, n ¼ 10–12 per group, one-way ANOVA followed by the
Bonferroni post hoc test.
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loss was circumscribed to the striatal region expressing themHtt
fragment.All these observations are congruentwithour previous
findings in primary cultures of striatal neurons expressing mHtt,
where loss of Ip preceded that of Fp (17), and was seen while
many other mitochondrial proteins showed nomajor expression
changes. Thus, the present observations are compatible with the
possibility that the relatively selective reduction in the expres-
sion and incorporation of the Ip protein in the C-II at the level
of the respiratory chain could lead to a general reduction in the
assembly and/or the stability of C-II and partial loss of its activ-
ity. Other studies reported preferential defects in C-II in Yeast
(23) and mammalian cell models expressing mHtt exon 1 (30).
Interestingly, transient changes in Ip subunit expression in
R6/2 mice have been described using a careful a large scale
proteomic analysis of the forebrain, with very early reduction
in the expression at 2 and 8 weeks of age (20). Such changes
were not seen in other studies in R6/2 mice, while C-II activity
tended to increase at early stage of the disease in YAC72
mice (31).
The defects in C-II have been consistently observed in the stri-
atumofHDpatients.Enzymatic activityofC-IIwaspreferentially
reducedin thestriatumofsymptomaticpatients,while thecerebral
cortex showed no significant modifications (15,16,32–36). Indi-
cations of C-II defects were also reported in muscle from HD
patients (37). The expression of the Ip protein is markedly
reduced in the caudate and putamen of symptomatic HD patients,
while the expression of many other mitochondrial proteins
remains essentially normal (17). Importantly, the loss of the Ip
protein was found to occur preferentially in the striatum, while
no significant reduction in expression could be observed in the
cerebral cortex and cerebellum ofHDpatients. A similar regional
analysis of the C-II assembly using BN-PAGE could not be
carried out in N171-82Q mice, since the method requires too
much material for mitochondria preparation. However, the
present western blot analysis of the striatum of R6/1 mice
showed a significant reduction in the total levels of Ip (assembled
and not assembled). Thus, it is possible that the loss of the C-II as-
sembly and activity and a reduction in Ip expression are phenom-
ena that preferentially affect the striatum.
The relationship between the different changes we observed
(Ip loss, C-II assembly defects, reduced C-II activity) is not yet
totally elucidated in terms of causality. The elucidation of the
mechanisms that could mediate the down-regulation of Ip
awaits further studies. A few working hypotheses have been
already discussed previously (17). The present observations
suggest that it may be a consequence of defective assembly
mechanisms leading to an increase in the rate of degradation of
the protein.
The defects in C-II may result from a mHtt-induced dysfunc-
tion of mitochondria. In the present study, we observed a reduc-
tion in mitochondrial biogenesis in N171-82Q mice. This is
consistent with the functional alteration of the PGC-1a
pathway in HD (14). PGC-1a is a co-activator of transcription
that plays a key role in stimulating mitochondrial biogenesis
through its action on the transcription factors NRF-1 and
NFR-2 (38,39). NRF-1 activates the transcription of mitochon-
drial genes, such as COX1 and cytochrome c. A well-
documented study showed that the promoter of the SDH-B
gene encoding for the Ip subunit has functional sites that bind
NRF-1 and NRF-2 in the proximity of the initiation site (40).
However, the hypothesis that the loss of PGC-1a is directly re-
sponsible for the loss of C-II is not compatible with the observa-
tion that levels of mRNA coding SDH-Ip or SDH-Fp are not
changed inHDpatients andmodels. Our in vitro study on striatal
neurons showed unchanged levels of the SDH-Ip mRNA, while
levels of the Ip protein were down regulated (17). In line with
this, SDH-Ip (and SDH-Fp) mRNA levels are not markedly
reduced in HD patients and mouse models as assessed by gene
arrays studies (41,42), while enzymatic C-II activity and Ip
levels are down regulated. Similarly, whereas SDH-Ip mRNA
expression is not changed in R6/2 mice, levels of the protein
vary depending on the age of the mice (20). Thus, Ip regulation
likely occurs at a post-transcriptional level.
One possible post-transcriptional regulatorymechanism of Ip
expression may be linked to the well-documented alterations of
mitochondrial membrane potential in HD (1). This could disturb
the import of C-II constituents, since the machinery of protein
import uses mitochondrial membrane potential (43).
The defects in the C-II assemblymay also result from the alter-
ation of specific molecular factors for import/assembly of Ip into
the complex. Destabilization of the C-II assemblymaymore pro-
foundly alter the levels of Ip when compared with the other subu-
nits of the complex. The proteins involved in the import of Ip and
more generally C-II subunits have not been identified in
mammals. The protein coded by TCMP62 in Yeast likely codes
a chaperone-like protein involved in the C-II assembly (44,45).
It is a membrane protein that interacts with SDHA and SDHB
gene products. Knockdown of TCMP62 leads to the loss of the
C-IIassembly.There isnoknownhomolog inmammals.SDHAs-
sembly Factor 1 (SDHAF1) has been recently found to be key
SDH assembly factor (46). Other few proteins have been identi-
fied to interact with Ip and Fp proteins, including human Frataxin
and itsYeastorthologYfh1p (47) and the proteinCART(cocaine-
and amphetamine-regulated transcripts) which is neuroprotective
in cell models of ischemia/hypoxia (48).
Post-transcriptional modification of the C-II subunit may also
regulate the C-II assembly. The C-II/SDH subunit Fp has been
shown to be regulated by acetylation. Recent experiments
showed that Fp is hyperacetylated in SIRT3 knockout mice
and SIRT3 directly deacetylates Fp in a nicotinamide adenine
dinucleotide (NAD)-dependent manner (49,50). Fu and colla-
borators demonstrated that mHtt leads to a decrease in SIRT3
activity (51). This may be a consequence of both reduced
PGC-1a as well as reduced NAD concentrations. Thus, loss of
SIRT3 in the HD context may lead to hyperacetylation of Fp,
reducing the assembly of Fp in C-II, perturbing the turnover of
Ip and eventually decreasing the enzymatic activity of C-II. A
loss of SIRT3 has been implicated in other neurodegenerative
diseases including Friedriech ataxia (52).
One important finding in the present study is that the overex-
pression of the SDH Ip subunit, and to a lesser extent, SDH Fp
exerts significant neuroprotective effects against mHtt in vivo.
This indicates, as suggestedbyourprevious in vitro experiments,
that loss of Ip in HD models may contribute to neurodegenera-
tion. This protective effect may appear at first surprising, since
lossof Ip is likelynot an early event in themolecular cascade trig-
geredbymHtt to kill neurons.Especially, the reducedexpression
of PGC-1a, mitochondrial biogenesis, altered mitochondrial
membrane potential, abnormal fragmentation and cristae disor-
ganization are likely preceding C-II loss and reduction in Ip
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levels.However, neurodegeneration signalingmight be seen as a
non-linear phenomenon rather resembling to a vicious cycle.
Overexpression of Ip (and similarly Fp) likely produces a stabil-
ization ofC-II levelswhichmayhave important consequences to
maintain energy production in the tricarboxylic acid (TCA)
cycle and electron flow in the respiratory chain. Ip may also
contribute to control reactive oxygen species (ROS) production
as suggested by others, since the Ip protein is considered to be a
potential ‘sensor’ of the ubiquinone pool in the mitochondria
(53). Although C-II is debated as a source of ROS by itself, com-
pelling evidence showed that disturbingC-II function at least in-
directly produces the elevation of ROS levels, and increased
ROS production is a well-documented feature of both HD trans-
genic mice and HD patients (54). Thus, the overexpression of Ip
and the improved stabilization of C-II may be sufficient to delay
striatal neuron demise. Our data suggest that while important
contributors of mHtt -induced energy perturbation (e.g. perturb-
ation of PGC-1a) are upstream of the deregulation of C-II by
mHtt, the consequent loss of the Ip protein is a key event contrib-
uting to the expression of neurodegeneration and that correcting
this anomaly retards the death/dysfunction of striatal neurons.
The lentiviral gene transfer approach for theoverexpressing Ip
protein should be so far considered as only a proof of principle
that in vivo, C-II may be an interesting therapeutic target for
slowing degeneration in HD. It would be of prime interest to
find small molecules that could increase Ip expression and C-II
stabilization or anaplerotic chemicals that bypass C-II defects
or improve TCA cycle and respiratory chain efficiency. Other
potential approaches would be to utilize agents which increase
the expression of PGC-1a (e.g. bezafibrate) or which improve
mitochondrial function as recently shown using the mitochon-
drial anti-oxidant XJB-5-131 (55,56). The results provide
further evidence that targeting mitochondrial dysfunction in




Four-month-old male Sprague-Dawley rats (Charles River)
were used. The animalswere housed in a temperature-controlled
roommaintained on a12 h light/dark cycle. Food andwaterwere
available ad libitum.Experimentswere performed in accordance
with the European Community Council directive 86/609/EEC
for the care and use of laboratory animals or were approved by
the Animal Care and Use Committee of the Weill Medical
College of Cornell University.
Transgenic mice
Transgenic mice expressing the wt-Htt (N171-18Q) and mHtt
(N171-82Q) N-terminal fragment of the human Htt (22), as
well as non-transgenic littermates were obtained from the
Jackson Laboratory (Bar Harbor, ME, USA) and bred at the
Weill Medical College of Cornell University animal facility.
Both male and female mice expressing wt-Htt or mHtt were
studied at various disease stages and compared with non-
transgenic age- and gender-matched littermates. In most experi-
ments, a similar number of male and female pairs were used. In
these mice, the symptomatic stage is characterized by
incoordination, ataxia and weight loss with onset at 3
months of age. Mice die prematurely at 6 months of age.
Male R6/1 transgenic mice expressing exon-1 of human mHtt
were obtained from Jackson Laboratory. Mice were genotyped
by PCR as described previously (21). Animals were bred at the
animal facility of the University of Barcelona. R6/1 mice were
used when they started to have motor coordination impairment
at 16 weeks of age (29).
Isolation of brain mitochondria
Non-synaptic brain mitochondria were isolated by a PercollTM
gradient purification method as described previously (57). All
procedures were conducted at 48C. Mice were sacrificed by de-
capitation and the forebrain was excised and homogenized in a
mannitol-sucrose isolation medium (225 mM mannitol, 75 mM
ultrapure sucrose, 5 mM N-2-hydroxyethylpiperazine-N′-2-
ethanesulfonic acid (HEPES), pH 7.4) containing 0.1 mg/ml
fatty acid-free bovine serum albumin (BSA) and 1 mM ethylene
glycol tetraacetic acid (EGTA). Homogenates were centrifuged
for 6 min at 2400g in a Beckmann L8-80 ultracentrifuge using a
50 TI rotor. The supernatant was collected and centrifuged for
14 min at 13 000g. The resulting pellet was resuspended in iso-
lation medium containing 15% PercollTM and 1 mM EGTA and
layered on the top of a discontinuous PercollTM gradient (23/
40%). The gradient was centrifuged for 14 min at 38 000g, and
the 23/40 inter-phase layer, containing the mitochondria, was
collected. Mitochondria were washed three times with isolation
medium without BSA and centrifuged for 14 min at 13 000g.
The pellet containing purified mitochondria was resuspended in
100 ml of isolation buffer without EGTA and BSA (58). Mito-
chondrial protein concentration was measured with a protein
assay kit (BioRad,Hercules, CA,USA), usingBSAas a standard.
Blue native PAGE
We have investigated by blue native gel electrophoresis the mo-
lecular organization of the mitochondrial respiratory chain.
BN-PAGE is ahigh-resolution electrophoretic techniqueused
for the isolation of membrane bound proteins (59). The solubil-
izationof biologicalmembranes in cellular ormitochondrial pre-
parations is obtained by applying mild detergents. Upon the
addition of the coomassie dye (Coomassie blue G-250) protein
aggregation is reduced, all the membrane proteins, and also
many water soluble, acquire a negative charge which pulls to
the anode during electrophoresis, irrespectively of their isoelec-
tric point.
Fiftymicrograms of the brainmitochondrial preparation were
resuspended in 50 ml of a BNmitochondria buffer (1.5 M amino-
caproic acid, 50 mM bis–tris, pH 7.0, at 48C) and then treated
with 2 ml of N-dodecylmaltoside (DDM; 10% w/v) on ice for
5′. Finally, samples were centrifuged for 30 min at 20 000g.
The supernatants were transferred to clean tubes and 5 ml of a
BN sample buffer (Coomassie Blue G-250 5% w/v suspension
in 750 mM 6-aminohexanoic acid, 50 mM bis–tris, 0.5 mM ethy-
lenediaminetetraacetic acid, pH 7.0, at 48C) was added to the
samples for BN-PAGE. Gels were cast as described for
BN-PAGE (60,61). We used 5–13% acrylamide gradient gels
with 4% sample gels on the top to separate DDM-solubilized in-
dividual mitochondrial complexes. Gels were run in a vertical
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electrophoresis apparatus under the conditions described for
BN-PAGE (61). Transfer of proteins onto a polyvinylidene
difluoride (PVDF) membrane (Amersham Biosciences) was
carried out overnight at 30 V at 48C. For immunodetection of
protein complexes, monoclonal antibodies (Molecular Probes)
against the following subunits were used: 39 kDa of complex
I, 70 kDa of complex II, core 2 of complex III, subunit I of
complex IV and subunit b of complex V. Native high molecular
weight markers were from Amersham Biosciences (59). For
protein loading control, the 10 ml of theDDM-treatedmitochon-
drial preparation was mixed to an equal amount of Laemmli
sample buffer and loaded in an SDS–PAGE. Transfer onto a
PVDF membrane was carried out as described above. Outer
(TOM20) or inner (TIM 23) membrane markers were immuno-
detected with a specific antibody (Santa Cruz). When the anti-
body against the 70 kDa (Fp) subunit was used, a reserve pool
of the not assembled 70 kDa subunit was immunodetected as a
second and lower molecular weight band in addition to the
fully assembled C-II band, normally detected around 130 kDa.
Depending on the daily hand-cast gradient gel preparation and
the bands migration, this protein would go undetected when
co-migrating with the Brilliant blue G in the dye front. Brain
mitochondria isolated from five animals of each genotype and
age group were compared as shown.
Oxygen consumption
The rate ofO2 consumptionwasmeasured in brainmitochondria
using a Clark oxygen electrode in a waterjacketed cell, magnet-
ically stirred at 378C (Hansatech Instruments, Norfolk, UK) as
previously described (62,63). Briefly 10 ml of freshly isolated
brain mitochondria was resuspended in a respiration medium
(125 mM KCl, 20 mM HEPES, 1 mM MgCl2, 2 mM KH2PO4,
pH 7.4). State 3 respiration was recorded in the presence of
0.4 mM adenosine di-phosphate. The state 3 rates were recorded
in the presence of glutamate:malate 5:1 mM or glutamate:succi-
nate 5:2 mM. State 4′ was induced with the specific inhibitor of
the Adenine Nucleotide Translocator, carboxy Atractilate. The
protein content in all samples was measured with a protein
assay kit (BioRad), using BSA as a standard. For oxygen con-
sumption, the comparison between wild-type and Tg was done
day by day to minimize variability due to isolation. Brain mito-
chondria isolated from six animals of each genotype and age
group were compared.
Quantitative real-time PCR
For the quantification of the relative amount of mitochondrial
DNA (mtDNA), total DNA was isolated from liquid nitrogen
frozen striatal sections of transgenic (N171-18Q and
N171-82Q), as well as non-transgenic mice, as described (64).
The mtDNA copy number was determined by qRT-PCR using
SYBR Green Chemistry on a Roche Light Cycler (Roche,
USA). The abundance of the mtDNA-encoded template [from
nucleotide (nt) 6409 to nt 6636] in the COX1 gene sequence
was assayed (primers: forward CAT CCC TTG ACA TCG
TG, reverse CTG AGT AGC GTC GTG G) and normalized
using a nuclear-encoded template for the 18S gene (primers:
forward CGGACAGGATTGACAGA, reverse: CCAGT-
CAGTGTAGCGC) (65). Each reaction was optimized and
confirmed over an appropriate linear concentration range using
genomic DNA standards. Samples were analyzed in duplicate
for both assays, enabling the calculation of the averagemtDNA:-
nuclear DNA ratio. The numbers of samples for these experi-
ments were as follows: for N171-82Q, n ¼ 7 at 1 and 2
months, n ¼ 5 at 3 months and n ¼ 6 at 4 months; for
N171-18Q: n ¼ 6 at 1 and 2 months of age and n ¼ 11 at 3 and
4 months of age.
Lentiviral vector production and intrastriatal injection
Vector production
The construction of SIN-W-PGK (mouse phosphoglycerate
kinase 1) vectors encoding Htt171-18Q and Htt171-82Q has
been described previously (26), as has the GFP construct (66).
Construct for overexpressing Fp and Ip proteins have been also
described previously (17,18). Viral particles were produced in
human embryonic kidney 293 T cells using a four-plasmid
system (67), collected by ultracentrifugation and suspended in
phosphate-buffered saline (PBS) with 1% BSA. The particle
content of the viral batches was determined by enzyme linked
immunosorbent assay for the p24 antigen (Gentaur, France).
Viral particles were used at a concentration of 200 000 ng of
p24 perml in 0.1 M PBSwith 1%BSA for intrastriatal injections.
Stereotaxic injection
Rats were anesthetized with ketamine/xylazine (75 and 10 mg/
kg, respectively; i.p.) and placed in a stereotaxic frame. Bilateral
stereotaxic injections into the striatum were made using a 30
gage blunt-tip steel needle connected to a 10 ml Hamilton
syringe (Hamilton, Reno, NV, USA) via a 30 cm polypropylene
catheter. Viral suspensions from the same batch were injected
into each striatum at 0.25 ml/min by means of an automatic in-
jector (Stoelting, Wood Dale, IL, USA), using the following
coordinates: 0.8 mm rostral to bregma, 3.5 mm lateral to
midline and 4.0 mm ventral to the skull surface, with the tooth
bar set at 3.3 mm (27). At the end of the injection, the needle
was left in place for 5 min, before being slowly withdrawn.
Brain tissue processing for histological evaluation
and biochemical analysis in rats
Histological evaluation
Rats received an overdose of sodium pentobarbital and were
transcardially perfused with phosphate buffer containing 4%
paraformaldehyde (PFA). Brains were then post-fixed in 4%
PFA for 24 h and then cryoprotected by immersion in 15 and
30% sucrose for 48 h. Coronal sections (thickness 40 mm)
were cut at 2228C using a sliding microtome (Cryocut 1800;
Leica Microsystems, Nussloch, Germany). Free-floating sec-
tions encompassing the entire striatum were serially collected
and stored in antifreeze cryoprotectant solution at 2208C until
immunohistochemical processing. Immunohistochemistry of
DARPP-32 (rabbit polyclonal antibody, Chemicon Intl. Inc.,
diluted 1:5000) and immunohistochemistry of EM48 (mouse
monoclonal antibody, MAB5374, Chemicon Intl. Inc., diluted
1:1000)were performed as described previously (27). Immunor-
eactivity was revealed using the Vectastain ABC Elite System
(Vector, Burlingham, CA, USA). The sections were mounted,
dehydrated by passing through ethanol and toluene and
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coverslippedwithEukitt. COXhistochemistrywas performed as
previously described according to the method of Wong-Riley
(68).
Determinationof striatalDARPP-32-andCOX-depleted volume
The volume of the striatum exhibiting a depletion of DARPP-32
staining was estimated as follows (27,28,69). The unstained
area of all serial striatal sections (400 mm apart) was manually
delineated using a 4× objective and an AX70 microscope
(Olympus, Munster, Germany) coupled with an image analysis
system.Thevolumewas thencalculatedaccording to theprinciple
ofCavalieri using the formula: volume¼ d(a1 + a2 + a3 + . . .),
where d is the distance between serial sections (400 mm), and a1,
a2, a3 etc. stand for the area showing lossofDARPP-32 immunor-
eactivity or loss ofCOXactivity (‘lesion’)within individual serial
sections throughout the striatum.
Determination of aggregate numbers
The number of EM48-positive inclusions was quantified as pre-
viously described (27) with the following modifications: the
inter-section distance was 400 mm (i.e. one in every 10 sections
was used) and observations were performed using a 10× object-
ive on a Leica DM6000 microscope equipped with a motorized
stage and an automated image acquisition and analysis system
(Mercator Software, Explora Nova, La Rochelle, France).
With this set-up, objects with an apparent cross-sectional area
.3 mm2 (i.e. diameter . 1.1 mm) could be reliably detected.
Counting and determination of cross-section areas of aggregates
were determined for 6000–12 000 EM48-positive objects per
striatum (i.e. 5–9 sections) in 8 rats/group.
SDH histo-enzymatic assay
Animals received an overdose of sodium pentobarbital and the
brain was removed and frozen in 2258C isopentane and stored
at 2808C. Coronal frozen sections (thickness 20 mm) were cut
at 2208C using a cryostat (3035S, Leica Microsystem). Histo-
chemical revelation of SDHactivitywas performed as described
previously (69,70). Succinate was used as the specific substrate,
and nitro blue tetrazolium (NBT) was used as electron acceptor,
which eventually forms formazan. Serial brain sections were
first incubated for 10 min in 0.1 M phosphate buffer and 0.9%
NaCl (PBS) at 378C to activate SDH,which is substantially inac-
tivated by tightly bound oxaloacetate (71). Sections were then
rinsed in a large volume of PBS and immersed in the reaction
medium containing 5 mM NBT, 0.05 M phosphate buffer (pH
7.6) 0.05 M sodium succinate for 40 min at 378C. Sections
were then rinsed in cold PBS for 5 min, immersed for few
seconds in deionized water and air-dried at room temperature.
During the staining procedure, care was taken to avoid sunlight,
which degrades NBT.
SDH activity analyses
Semi-quantitative analysis of SDH activity in the entire striatum
was performed using densitometry analysis (using MCID soft-
ware) as described previously (69,70). In the case of the analysis
of the entire striatum, 8–10 animals per group were examined.
For subregional analysis of SDH activity in the striatum based
on the visualization of the expression of GFP, acquired image
of SDH-stained section was aligned with the adjacent section
imaged for GFP fluorescence using a Zeiss Axioplan2 Imaging
microscope, a ×1.25 objective and cooled CCD camera and
an image acquisition and analysis system (Mercator, Explora
Nova). For each animal, region of interest was delineated on
the GFP images (5–12 sections, 200 mm interspace), pasted
and translated to be located at the same anatomical level on the
SDH image for the determination of optical density in the
region. The mean+SEM SDH OD unit in the GFP-containing
area was calculated from all animals. For these analyses, three
to four animals were studied in each group.
3D reconstruction of SDH activity
Images of serial sections revealed for SDH histochemistry were
digitized using a flatbed scanner (ImageScanner; GE Healthcare
Europe, Orsay, France) with 600 dpi resolution (pixel size 42 ×
42 mm2). 3D post-mortem reconstruction was performed using
the in-house BrainRAT software freely available on internet
(http://brainvisa.info)basedonapropagativeco-registrationstrat-
egy. On all coronal sections (n ¼ 18 serial sections/brain) sepa-
rated by 200 mm, the loss of staining seen as a palor in the
striatum infectedwith lenti-Htt171-82Qwasmanually segmented
in 3D, and corresponding lateralized areas were symmetrically
computed in the control (lenti-Htt171-18Q) striatum. Image pro-
cessing techniques used were described in previous work (72).
Statistical analysis
All data were expressed as the means+SEM. Unpaired Stu-
dent’s t-test was used for the comparison between two groups.
When more than two groups were compared, a one-way
ANOVA with multiple comparisons using the post hoc Bonfer-
roni test was carried out using commercially available software
(StatVieww software, SAS Institute Inc., USA). A two-way
ANOVA followed by a post hoc Bonferroni/Dunn test was
used for the analysis of SDH activity throughout the antero-
posterior anatomical extension of the striatum in rats infected
with lentiviral vectors. For time-dependent changes in mtDNA
levels, data were analyzed by two-way ANOVA (ages/geno-
types) and pairwise multiple comparison procedures (Holm-
Sidak method). For all statistical tests performed, a probability
level of 5% was considered significant.
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